Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All drugs

NN3201 (KIT Antibody-drug Conjugate, MMAE)

Stage Phase 1

Sponsor Novelty Nobility

Modality antibody-drug conjugate

Class KIT-directed ADC

Target KIT (TEC-0117)

Sources

publication, as of 2026-11-07

https://pubmed.ncbi.nlm.nih.gov/40368739/

PDGFRA D842V-mutated GISTs account for about 5% to 10% of all GISTs ... Less than 1% of KIT/PDGFRA WT GISTs harbor BRAF mutations ... GISTs with NTRK gene fusions have been identified ... Other rare drivers include NF1 (somatic or germline), PIK3CA, RAS, and FGFR family translocations.

Review, Hematol Oncol Clin North Am 2025, DOI 10.1016/j.hoc.2025.04.006, PMID 40368739, text and Table 1

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT06805825

A Phase 1 Dose Escalation and Expansion Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 in Subjects With Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

NCT06805825

Registry NCT06805825

Phase Phase 1

Status Recruiting

Enrollment 67

Start 2025-02-03

Primary completion 2027-08-30

Study completion 2027-12-31

Catalyst Primary completion. 08.30.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.